Literature DB >> 21606224

Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009.

Supriya D Mehta1, Ian Maclean, Jeckoniah O Ndinya-Achola, Stephen Moses, Irene Martin, Allan Ronald, Lawrence Agunda, Ruth Murugu, Robert C Bailey, Johan Melendez, Jonathan M Zenilman.   

Abstract

We evaluated antimicrobial resistance in Neisseria gonorrhoeae isolated from men enrolled in a randomized trial of male circumcision to prevent HIV. Urethral specimens from men with discharge were cultured for N. gonorrhoeae. MICs were determined by agar dilution. Clinical and Laboratory Standards Institute (CLSI) criteria defined resistance: penicillin, tetracycline, and azithromycin MICs of ≥2.0 μg/ml; a ciprofloxacin MIC of ≥1.0 μg/ml; and a spectinomycin MIC of ≥128.0 μg/ml. Susceptibility to ceftriaxone and cefixime was shown by an MIC of ≤0.25 μg/ml. Additionally, PCR amplification identified mutations in parC and gyrA genes in selected isolates. From 2002 to 2009, 168 N. gonorrhoeae isolates were obtained from 142 men. Plasmid-mediated penicillin resistance was found in 65%, plasmid-mediated tetracycline resistance in 97%, and 11% were ciprofloxacin resistant (quinolone-resistant N. gonorrhoeae [QRNG]). QRNG appeared in November 2007, increasing from 9.5% in 2007 to 50% in 2009. Resistance was not detected for spectinomycin, cefixime, ceftriaxone, or azithromycin, but MICs of cefixime (P = 0.018), ceftriaxone (P < 0.001), and azithromycin (P = 0.097) increased over time. In a random sample of 51 men, gentamicin MICs were as follows: 4 μg/ml (n = 1), 8 μg/ml (n = 49), and 16 μg/ml (n = 1). QRNG increased rapidly and alternative regimens are required for N. gonorrhoeae treatment in this area. Amid emerging multidrug-resistant N. gonorrhoeae, antimicrobial resistance surveillance is essential for effective drug choice. High levels of plasmid-mediated resistance and increasing MICs for cephalosporins suggest that selective pressure from antibiotic use is a strong driver of resistance emergence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606224      PMCID: PMC3147659          DOI: 10.1128/AAC.00155-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Porin variation among clinical isolates of Neisseria gonorrhoeae over a 10-year period, as determined by Por variable region typing.

Authors:  Durrie L McKnew; Freyja Lynn; Jonathan M Zenilman; Margaret C Bash
Journal:  J Infect Dis       Date:  2003-04-02       Impact factor: 5.226

2.  European surveillance of antimicrobial resistance in Neisseria gonorrhoeae.

Authors:  Michelle J Cole; Stephanie A Chisholm; Steen Hoffmann; Angelika Stary; Catherine M Lowndes; Catherine A Ison
Journal:  Sex Transm Infect       Date:  2010-11       Impact factor: 3.519

3.  Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae.

Authors:  Sho Takahata; Nami Senju; Yumi Osaki; Takuji Yoshida; Takashi Ida
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Antibiotic susceptibility pattern of gonococcal isolates.

Authors:  S K Jain; M G Kulkarni; D D Banker
Journal:  Indian J Med Sci       Date:  1994-10

5.  Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains.

Authors:  David M Whiley; Susanne Jacobsson; John W Tapsall; Michael D Nissen; Theo P Sloots; Magnus Unemo
Journal:  J Antimicrob Chemother       Date:  2010-10-12       Impact factor: 5.790

6.  Efficacy of gentamicin and kanamycin in the treatment of uncomplicated gonococcal urethritis in Zambia.

Authors:  S K Hira; V R Attili; J Kamanga; O Mkandawire; J S Patel; M I Patel
Journal:  Sex Transm Dis       Date:  1985 Jan-Mar       Impact factor: 2.830

7.  Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies.

Authors:  Julie A Giles; Jason Falconio; Jeffrey D Yuenger; Jonathan M Zenilman; Michael Dan; Margaret C Bash
Journal:  J Infect Dis       Date:  2004-04-30       Impact factor: 5.226

8.  Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: association with HIV seropositivity.

Authors:  D A Lewis; L Scott; M Slabbert; S Mhlongo; A van Zijl; M Sello; N du Plessis; F Radebe; E Wasserman
Journal:  Sex Transm Infect       Date:  2008-07-02       Impact factor: 3.519

9.  Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.

Authors:  Mark Pandori; Pennan M Barry; Abel Wu; Alyssa Ren; William L H Whittington; Sally Liska; Jeffrey D Klausner
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Gentamicin in the treatment of infections due to penicillinase-producing gonococci.

Authors:  N J Tan; V S Rajan; R Pang; E H Sng
Journal:  Br J Vener Dis       Date:  1980-12
View more
  17 in total

1.  Gentamicin Susceptibility among a Sample of Multidrug-Resistant Neisseria gonorrhoeae Isolates in India.

Authors:  Manju Bala; Vikram Singh; Aradhana Bhargava; Monika Kakran; Naveen Chandra Joshi; Ravi Bhatnagar
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

2.  Emergence of fluoroquinolone resistance in Neisseria gonorrhoeae isolates from four clinics in three regions of Kenya.

Authors:  Philippe R S Lagace-Wiens; Sarah Duncan; Joshua Kimani; Alexander Thiong'o; Juma Shafi; Scott McClelland; Eduard J Sanders; George Zhanel; Nicholas Muraguri; Supriya D Mehta
Journal:  Sex Transm Dis       Date:  2012-05       Impact factor: 2.830

3.  Antimicrobial Susceptibility Testing Patterns of Neisseria gonorrhoeae from Patients Attending Sexually Transmitted Infections Clinics in Six Regions in Tanzania.

Authors:  Said Aboud; Simon N Buhalata; Onduru G Onduru; Mercy G Chiduo; Gideon P Kwesigabo; Stephen E Mshana; Alphaxard M Manjurano; Mansuet M Temu; Coleman Kishamawe; John M Changalucha
Journal:  Trop Med Infect Dis       Date:  2022-06-02

4.  Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial.

Authors:  Jenell Stewart; Elizabeth Bukusi; Fredericka A Sesay; Kevin Oware; Deborah Donnell; Olusegun O Soge; Connie Celum; Josephine Odoyo; Zachary A Kwena; Caitlin W Scoville; Lauren R Violette; Susan Morrison; Jane Simoni; R Scott McClelland; Ruanne Barnabas; Monica Gandhi; Jared M Baeten
Journal:  Trials       Date:  2022-06-16       Impact factor: 2.728

5.  Sexually transmitted infections and male circumcision: a systematic review and meta-analysis.

Authors:  Robert S Van Howe
Journal:  ISRN Urol       Date:  2013-04-16

Review 6.  The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.

Authors:  Daniel H F Rubin; Jonathan D C Ross; Yonatan H Grad
Journal:  Transl Res       Date:  2020-02-29       Impact factor: 7.012

Review 7.  Antibacterial resistance in sub-Saharan Africa: an underestimated emergency.

Authors:  Samuel Kariuki; Gordon Dougan
Journal:  Ann N Y Acad Sci       Date:  2014-03-14       Impact factor: 5.691

8.  TaqMan real-time quantitative PCR assay for detection of fluoroquinolone-resistant Neisseria gonorrhoeae.

Authors:  LiHong Zhao; ShuPing Zhao
Journal:  Curr Microbiol       Date:  2012-09-02       Impact factor: 2.188

9.  Phenotypic and genetic characterisation of bacterial sexually transmitted infections in Bissau, Guinea-Bissau, West Africa: a prospective cohort study.

Authors:  Birgitta Olsen; Fredrik Månsson; Cidia Camara; Mario Monteiro; Ansu Biai; Alfredo Alves; Sören Andersson; Hans Norrgren; Magnus Unemo
Journal:  BMJ Open       Date:  2012-03-20       Impact factor: 2.692

10.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.